Responses of patients with juvenile idiopathic arthritis to methotrexate: a genomic outlook

Selvestrel, Davide; Lucafò, Marianna; Pugnetti, Letizia; Pagarin, Sofia; Moressa, Valentina; Pastore, Serena; Taddio, Andrea; Stocco, Gabriele; Decorti, Giuliana

doi:10.1080/1744666x.2021.1968833

Cited by 1 publication

(2 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9 Bristol Myers Squibb, Immunology and Fibrosis, Princeton, NJ, USA. 10 Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Università degli Studi di Genova, Genoa, Italy. 11 IRCCS Istituto Giannina Gaslini, Gaslini Trial Centre/ Servizio di Sperimentazioni Cliniche Pediatriche, PRINTO, Genoa, Italy.…”

Section: Supplementary Informationunclassified

“…Reliable, validated serum biomarkers of treatment response in JIA are needed to guide clinical decisions to allow patients to be treated with the most effective therapy as early as possible [ 9 ]. In particular, a high proportion of patients with JIA show incomplete response to MTX [ 10 ]. As such, strategies of combining biomarkers with options to treat JIA have been proposed [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis

Brunner,

Schulert,

Sproles

et al. 2024

Arthritis Res Ther

View full text Add to dashboard Cite

Background Juvenile idiopathic arthritis (JIA) comprises a heterogeneous group of conditions that can cause marked disability and diminished quality of life. Data on predictors of clinical response are insufficient to guide selection of the appropriate biologic agent for individual patients. This study aimed to investigate the propensity of S100A8/9 and S100A12 as predictive biomarkers of abatacept response in polyarticular-course juvenile idiopathic arthritis (pJIA). Methods Data from a phase 3 trial (NCT01844518) of subcutaneous abatacept in patients with active pJIA (n = 219) were used in this exploratory analysis. Association between biomarker levels at baseline and improvements in JIA-American College of Rheumatology (ACR) criteria responses or baseline disease activity (measured by Juvenile Arthritis Disease Activity Score in 27 joints using C-reactive protein [JADAS27-CRP]) were assessed. Biomarker level changes from baseline to month 4 were assessed for disease outcome prediction up to 21 months. Results At baseline, 158 patients had available biomarker samples. Lower baseline S100A8/9 levels (≤ 3295 ng/mL) were associated with greater odds of achieving JIA-ACR90 (odds ratio [OR]: 2.54 [95% confidence interval (CI): 1.25–5.18]), JIA-ACR100 (OR: 3.72 [95% CI: 1.48–9.37]), JIA-ACR inactive disease (ID; OR: 4.25 [95% CI: 2.03–8.92]), JADAS27-CRP ID (OR: 2.34 [95% CI: 1.02–5.39]) at month 4, and JIA-ACR ID (OR: 3.01 [95% CI: 1.57–5.78]) at month 16. Lower baseline S100A12 levels (≤ 176 ng/mL) were associated with greater odds of achieving JIA-ACR90 (OR: 2.52 [95% CI: 1.23–5.13]), JIA-ACR100 (OR: 3.68 [95% CI: 1.46–9.28]), JIA-ACR ID (OR: 3.66 [95% CI: 1.76–7.61]), JIA-ACR90 (OR: 2.03 [95% CI: 1.07–3.87]), JIA-ACR100 (OR: 2.14 [95% CI: 1.10–4.17]), and JIA-ACR ID (OR: 4.22 [95% CI: 2.15–8.29]) at month 16. From baseline to month 4, decreases in S100A8/9 and S100A12 generally exceeded 50% among JIA-ACR90/100/ID responders. Conclusion Lower baseline levels of S100A8/9 and S100A12 proteins predicted better response to abatacept treatment than higher levels and may serve as early predictive biomarkers in pJIA. Decreases in these biomarker levels may also predict longer-term response to abatacept in pJIA.

show abstract

Section: Supplementary Informationunclassified

Section: Introductionmentioning

confidence: 99%